350 FIFTH AVENUE, NEW YORK, NY
Market cap: $349.6M (12/18/2025)
Price: $3.23
Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Changes in Board, Management or Compensation
Other Events
News, Material Contracts
FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease
Q3
Q2
Q1
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Effectiveness Notice
Certificate
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Notice of Proposed Sale of Securities
Post-Effective Amendment to Registration Statement